BR112019009565A2 - método de avaliação da cinética molecular e método de rastreamento - Google Patents

método de avaliação da cinética molecular e método de rastreamento

Info

Publication number
BR112019009565A2
BR112019009565A2 BR112019009565A BR112019009565A BR112019009565A2 BR 112019009565 A2 BR112019009565 A2 BR 112019009565A2 BR 112019009565 A BR112019009565 A BR 112019009565A BR 112019009565 A BR112019009565 A BR 112019009565A BR 112019009565 A2 BR112019009565 A2 BR 112019009565A2
Authority
BR
Brazil
Prior art keywords
proteolysis
human
affinity
specific protein
molecular kinetics
Prior art date
Application number
BR112019009565A
Other languages
English (en)
Inventor
Miyamoto Etsuko
Ozawa Masaaki
Original Assignee
Univ Tokyo Science Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokyo Science Found filed Critical Univ Tokyo Science Found
Publication of BR112019009565A2 publication Critical patent/BR112019009565A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

é fornecido um método de avaliação de cinética molecular que envolve: uma etapa para dosar um animal humano ou não humano com uma molécula indutora de proteólise, que é um conjugado de um marcador de indução de proteólise, isto é, uma molécula que tem afinidade por protease e que não inibe a proteólise por protease e uma molécula de afinidade da proteína específica tendo afinidade por uma proteína específica e induzindo a proteólise da proteína específica in vivo no animal humano ou não humano; e uma etapa para avaliação da cinética molecular das moléculas de afinidade da proteína específica ou as moléculas indutoras de proteólise pela detecção da proteólise das proteínas específicas em uma amostra que é pelo menos parte do animal humano ou não humano.
BR112019009565A 2016-11-15 2017-11-13 método de avaliação da cinética molecular e método de rastreamento BR112019009565A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016222682 2016-11-15
PCT/JP2017/040780 WO2018092724A1 (ja) 2016-11-15 2017-11-13 分子動態評価方法及びスクリーニング方法

Publications (1)

Publication Number Publication Date
BR112019009565A2 true BR112019009565A2 (pt) 2019-10-08

Family

ID=62146505

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019009565A BR112019009565A2 (pt) 2016-11-15 2017-11-13 método de avaliação da cinética molecular e método de rastreamento

Country Status (10)

Country Link
US (1) US20190369111A1 (pt)
EP (1) EP3543349A4 (pt)
JP (1) JP7093110B2 (pt)
KR (1) KR20190085955A (pt)
CN (1) CN110036116A (pt)
AU (1) AU2017361156A1 (pt)
BR (1) BR112019009565A2 (pt)
CA (1) CA3043806A1 (pt)
IL (1) IL266629A (pt)
WO (1) WO2018092724A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3312273A4 (en) 2015-06-19 2019-07-03 Tokyo University of Science Foundation LABEL INDUCING DEGRADATION OF PROTEINS AND USE THEREOF
AU2017361157A1 (en) 2016-11-15 2019-06-06 Tokyo University Of Science Foundation p53 degradation inducing molecule and pharmaceutical composition
MY195945A (en) * 2016-11-15 2023-02-27 Univ Tokyo Science Found Ras Protein Degradation Inducing Molecule and Pharmaceutical Composition
CN112662693A (zh) * 2021-01-15 2021-04-16 华东理工大学 用于Nrf2降解剂的筛选体系、表达载体、宿主细胞及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016589A2 (en) * 2005-08-02 2007-02-08 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
WO2008123266A1 (ja) 2007-03-19 2008-10-16 Reverse Proteomics Research Institute Co., Ltd. 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
JP2011022002A (ja) 2009-07-15 2011-02-03 Tmrc Co Ltd 抗癌剤候補物質の評価方法
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
SG186389A1 (en) * 2010-06-30 2013-01-30 Univ Brandeis Small-molecule-targeted protein degradation
EP3608317A1 (en) * 2012-01-12 2020-02-12 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
WO2016105518A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3312273A4 (en) * 2015-06-19 2019-07-03 Tokyo University of Science Foundation LABEL INDUCING DEGRADATION OF PROTEINS AND USE THEREOF

Also Published As

Publication number Publication date
AU2017361156A1 (en) 2019-06-06
WO2018092724A1 (ja) 2018-05-24
US20190369111A1 (en) 2019-12-05
JPWO2018092724A1 (ja) 2019-10-17
JP7093110B2 (ja) 2022-06-29
IL266629A (en) 2019-07-31
EP3543349A4 (en) 2020-08-05
CA3043806A1 (en) 2018-05-24
KR20190085955A (ko) 2019-07-19
EP3543349A1 (en) 2019-09-25
CN110036116A (zh) 2019-07-19

Similar Documents

Publication Publication Date Title
BR112019009565A2 (pt) método de avaliação da cinética molecular e método de rastreamento
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112017004899A2 (pt) detecção de proteínas mal dobradas
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
BR112015022934A2 (pt) esteroides neuroativos, composições, e uso do mesmo
BR112017008165B8 (pt) anticorpo de domínio único direcionado contra um componente intracelular e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR112018071583A2 (pt) métodos para determinar dpp3 e métodos terapêuticos
BR112016024515A2 (pt) proteínas do agonista do receptor trail de cadeia única
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
BR112015015086A2 (pt) calibração de válvula de fluido acústico
BR112018072723A2 (pt) composição, e, métodos para tratar uma doença em um sujeito e para aumentar uma resposta imunológica em um sujeito
BR112016028534A2 (pt) ceramidas e seu uso em diagnosticar cvd
MX2015013436A (es) Metodo de determinacion del sexo de un embrion en un huevo.
BR112016019740A2 (pt) monitoramento do estado de inflamação
BR112018010764A2 (pt) método para detectar atividade bacteriana em uma amostra biológica e unidade de detecção correspondente
BR112018013801A2 (pt) ?anticorpo, peptídeo, molécula de ácido nucleico, vetor, célula ou animal não humano, composição, kit, usos de um anticorpo, de um peptídeo, de uma molécula, ou de um vetor, métodos para determinar se células que expressam cd9 estão presentes em uma amostra, para produzir um anticorpo ou parte funcional ou equivalente funcional, para tratar e/ou evitar um distúrbio associado às células que expressam cd9 e para produzir uma célula imune específica para cd9 ou um anticorpo específico para cd9, método ex vivo para determinar se um indivíduo está sofrendo de um câncer positivo para cd9, composição imunogênica, e, kit de diagnóstico?
BR112019005167A2 (pt) método e kit para analisar uma amostra
BR112019005172A2 (pt) método e kit para analisar uma amostra
BR112014031841A2 (pt) formulação farmacêutica
BR112016024624A2 (pt) produto de combinação para detectar marcador alvo
BR112016024730A2 (pt) dispositivo, método e conjunto de análise imunocromatográfica
BR112016000585A2 (pt) modificações quimioenzimáticas sítio-específicas de proteína
BR112015004631A2 (pt) marcadores genéticos de resistência à mastite
EA201991464A1 (ru) АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ
BR112015018265A2 (pt) Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements